Stage III B or stage IV non-small cell lung cancer (not a candidate for local therapies with curative intent) MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Interventions
Trade Name: CABOMETYX - 60 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE
Product Name: CABOZANTINIB
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: CABOZANTINI
Sponsors
FONDAZIONE RICERCA TRASLAZIONALE (FORT)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Citological or histological diagnosis of NSCLC non-small-cell-lung cancer (NSCLC) stage III B (notn suitable for local treatments with curative intent) or stage IV. 2. Tissue samples available for MET analysis (archivial tissue or tissue collected at study entry); patients without archival tumor tissue or refusing new biopsy at study entry, are eligible if MET mutation is detected in cf-DNA 3. Presence of MET mutations (exon 14 skipping mutation ONLY) detected in tissue or cf-DNA at the local lab or in the central lab or MET amplification (MET/CEP7 ratio > 2.2) detected in the central lab ONLY. 4. Measurable disease according to RECIST criteria version 1.1 5. At least 1 prior line of standard therapy (chemotherapy and/ or immunotherapy) 6. Performance status 0-1 (ECOG) 7. Age =18 years 8. Patients potentially fertile using adequate methods of contraception in order to avoid childbearing. Contraceptive methods must be respected by male and female patients and their partners during study treatment period and at least 4 months after completing therapy 9. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to enrollment: 7.a. ANC = 1500 cells/µL without granulocyte colony-stimulating factor support 8.b. Platelet count = 100,000/µL without transfusion 9.c. Hemoglobin = 9.0 g/dL Patients may be transfused to meet this criterion d. AST, ALT, and alkaline phosphatase = 2.5 × ULN, with the following exceptions: - Patients with documented liver metastases: AST and/or ALT = 5 × ULN Patients with documented liver or bone metastases: alkaline phosphatase = 5 × ULN. e. Serum bilirubin = 1.25 × ULN f. Patients with known Gilbert disease who have serum bilirubin level = 3 × ULN may be enrolled g. Calculated creatinine clearance (CRCL) = 45 mL/min or, if using cisplatin, calculated CRCL must be = 60 mL/min 10. Patient compliance to the study procedure 11. Written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 13 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 12
Exclusion criteria
Exclusion criteria: 1. Tissue sample not available in patients without MET exon 14 skipping mutation detected in cf-DNA 2. No possibility to assess MET status 3. Absence of any measurable disease according to RECIST criteria 4. Co-existence of driver events, including EGFR mutations, KRAS mutations, ALK rearrangements or ROS-1 rearrangements 5. No prior therapy 6. Concomitant chemotherapy or immunotherapy or radiotherapy 7. Symptomatic brain metastasis 8. Uncontrolled significant inter-current or recent illness, including cardio-vascular disorders and gastro-intestinal disorders 9. Major surgery within 2 months before first dose of study treatment 10. Concomitant anti-coagulation with oral anti-coagulants or plated inhibitors 11. History of significant bleeding, trachea-bronchial tree/major blood vessels invading tumors, cavity pulmonary lesions and GI disorders associated with a risk of perforation or fistula formation 12. Diagnosis of another cancer in the last 3 years, except for in situ carcinoma of cervix, breast and bladder or skin carcinoma (squamous or basalioid) 13. Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the efficacy in term of response rate (RR) of Cabozantinib in NSCLC patients with MET amplification or MET exon 14 skipping mutation pretreated or not with MET inhibitors.;Secondary Objective: Not applicable;Primary end point(s): Response Rate (RR) (complete + partial responses) of Cabozantinib in NSCLC patients with MET amplification or MET exon 14 skipping mutation pre-treated or not with MET inhibitors.;Timepoint(s) of evaluation of this end point: Disease evaluation will be performed according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. every two months (8 weeks) until disease progression, unacceptable toxicity or patient refusal | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Progression free survival (PFS) - Overall survival (OS) - Disease Control Rate (DCR: malattia stabile + risposta parziale + risposta completa) - Biomarkers esploratori su sangue o tessuto (per ogni paziente arruolato nello studio potrà essere facoltativamente donato un campione di tessuto alla progressione di malattia) ;Timepoint(s) of evaluation of this end point: Disease evaluation will be performed according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. every two months (8 weeks) until disease progression, unacceptable toxicity or patient refusal | — |
Countries
Italy
Contacts
Public ContactCRO
Clinical Research Technology
Outcome results
None listed